| 1978N-0065 | Skin Bleaching Drug Products | |||||||||||||||||||||||
| FDA Comment Number : | EC533 | |||||||||||||||||||||||
| Submitter : | Dr. Shari Clarke | Date & Time: | 12/27/2006 08:12:45 | |||||||||||||||||||||
| Organization : | Dr. Shari Clarke | |||||||||||||||||||||||
| Category : | Health Professional | |||||||||||||||||||||||
| Issue Areas/Comments | ||||||||||||||||||||||||
| GENERAL | ||||||||||||||||||||||||
| GENERAL | ||||||||||||||||||||||||
| It is so important that hydroquinone remains on the market. There are no human studies supporting the theory that hydroquinone is associated with cancer and the studies that have been conducted were on animals with high oral doses of hydroquinone (which is not how we use this medication). I urge you to reconsider its withdrawal from the market as many patient benefit from its use. | ||||||||||||||||||||||||